PYLARIFY® PET/CT was well tolerated across multiple studies including 593 men with PCa1

Adverse reactions that occurred in >0.5% of
men who received PYLARIFY® (n=593)*

Table showing adverse reaction rates from PYLARIFY® clinical trials. Table showing adverse reaction rates from PYLARIFY® clinical trials.

*In addition, a hypersensitivity reaction was reported in 1 patient (0.2%) with a history of allergic reactions.

REVIEW CASE STUDIES FROM PYLARIFY® CLINICAL TRIALS

LEARN MORE

PCa=prostate cancer.

IMPORTANT SAFETY
INFORMATION

Contraindications

None.

Warnings and Precautions

Reference

  1. PYLARIFY® [package insert]. North Billerica, MA: Progenics Pharmaceuticals, Inc., a Lantheus company